發展以血中微型 RNA 作為冠心症(CAD)的非侵入性疾病指標

以作者查詢圖書館館藏

、以作者查詢臺灣博碩士

、以作者查詢全國書目

、勘誤回報

、線上人數：63

、訪客IP：18.220.112.210

姓名

賴柏丞(Bo-Cheng Lai) 查詢紙本館藏

畢業系所

系統生物與生物資訊研究所

論文名稱

發展以血中微型 RNA 作為冠心症(CAD)的非侵入性疾病指標
(Exploration of microRNAs as non-invasive biomarkers for coronary artery disease (CAD))

相關論文

★ 探討牛樟芝CCM111對細胞訊息傳遞之影響	★ Tyloxapol 在大腸癌細胞中的特異性及作用機制之研究
★ MAPK傳導路徑相關微型RNA在黑色素瘤細胞中功能之研究	★ 利用MAPK訊息傳導路徑相關的miRNAs來治療BRAF抑制劑的抗藥性在黑色素瘤細胞中之研究
★ 探討miR-567在黑色素細胞瘤中的調控機制	★ 探索微型核糖核酸與慢性腎臟病及血液透析病人泌尿道上皮癌生物標記的相關性
★ 以miRNA為基礎開發偵測放射線治療抗性及預後的生物標記	★ 偵測微型核糖核酸 miR-524-5p表現量利用原位雜交染色法來作為輔助診斷惡性黑色素瘤的生物標記之研究
★ 研究牛樟芝萃取物 CCM111 的作用機制	★ 探討黑色素腫瘤中p53調控miR-524-5p及miR-596表現之機制
★ 泌尿道上皮癌相關的miRNAs在膀胱癌之研究	★ 探討BRAF抑制劑透過細胞間訊息誘導腫瘤形成之研究
★ 微型核糖核酸成為放射線治療的預後生物標記之研究	★ microRNAs作為放射治療預後之生物標誌物與miR-148a-3p於頭頸癌放射敏感度之研究
★ 研究miR-524-5p和miR-567治療在黑色素瘤與BRAF抑製劑的抗藥性黑色素瘤	★ 包覆性腹膜硬化症相關miRNAs在腹膜纖維化之研究

檔案

[Endnote RIS 格式]

[Bibtex 格式]

[相關文章]

[文章引用]

[完整記錄]

[館藏目錄]

至系統瀏覽論文 (2026-8-19以後開放)

摘要(中)

MicroRNA(miRNA)是近年來一種被廣為研究的項目之一，且被認為是轉錄後基因的重要調節關鍵，更與一些癌症疾病的產生有關，可以用於相關的治療。
冠心症(Coronary artery diease, CAD)是一種心血管疾病，成因通常為供給心臟氧氣的粥狀動脈變得狹窄或冠狀動脈被斑塊(plaque)所阻塞造成心肌細胞缺氧而發生的。由於CAD的致死率高，且目前準確的早期診斷方法較缺乏，若是可以找出一可行的生物標記去做準確的早期預測，應該可以改善CAD致死率。
而miRNAs可以由周邊體液採集並分離而得，容易取得且穩定性也高，我們希望可以發展一由miRNAs組成的非侵入性診斷標記。根據研究指出，miRNAs和一些代謝和內分泌是相關的，而這些代謝或內分泌可能影響了CAD的發展，故我們認為miRNAs是有潛力發展成可行的CAD預測標靶。
本實驗採用世代研究法(cohort study)，運用了一群原先健康的群體資料，追蹤其從健康到發病間的變化，藉由聯新國際醫院生物資料庫中取得四組同一受試者在未罹患冠心症及已罹患冠心症之血液樣本，並利用高通量qPCR和microRNA PCR array (為定量microRNA的實驗方法)及miRNA 次世代定序的方式去分析四組受試者血液樣本之間的miRNAs表現量差異，結果發現有些miRNAs是有明顯的區別，因此挑選出15個有潛力的miRNAs。之後又收144位受試者的血清利用Real time PCR 定量其miRNA，篩選出來15個候選miRNAs再經過144 例臨床個案之樣本作為訓練組後計算，建立出的組合公式，可明顯區分出ACS病患與3年內皆未得ACS。模型公式所顯示出最佳曲線下面積（AUC）為0.96並且敏感度（91 ％）和特異度（87.8 ％）。

摘要(英)

MicroRNA (miRNA) is one of the most widely studied topics in recent years, and is considered to play an important role to the regulation of post-transcriptional genes. It is also related to the occurrence of some cancer diseases and can be used for related treatments.
Coronary artery disease (CAD) is a cardiovascular disease that usually occurs when the atherosclerotic arteries that carries oxygen to the heart becomes narrowed or the coronary arteries are blocked by plaques, causing myocardial cell hypoxia. Owing to the high mortality rate of CAD and the lack of accurate early diagnosis methods, if a suitable biomarker can be found for early prediction, it should improve the mortality rate of CAD.
And miRNAs can be collected and separated from surrounding body fluids, which are easy to get and have high stability. We hope to develop a non-invasive diagnostic marker composed of miRNAs. According to previous study, miRNAs are related to some metabolisms and endocrines, and these metabolisms or endocrines may affect the development of CAD. Therefore, we believe that miRNAs have the potential to develop into reliable CAD biomarker.
This screen subjects were selected from a cohort study, using a selected group data to track its changes from health to onset. We collected blood samples from the same patient before and after ACS occurrence from Landseed cohort database. High-throughput quantification real-time PCR arrays and next generation sequencing (NGS) of miRNA were used to analyses the expression difference before and after ACS occurrence among 4 patients. The results indicate there are 15 potential miRNAs displayed significant differences The candidate miRNAs were then verifed by single qRT-PCR assays from 144 serum samples. The miRNA classifier for ancillary ACS detection was developed by multiple logistic regression analyses. The ROC analysis of the miRNA and TG classifier showed discrimination between ACS and non ACS patients and found that the area under curve (AUC) was 0.96. The classifier had a sensitivity of 91% and a specificity of 87.8%.

關鍵字(中)

★ 冠心症
★ 微型RNA

關鍵字(英)

★ Coronary artery diease
★ microRNA

論文目次

中文摘要.…………………………………………………………………………….v
Abstract ……………………………………………………………………………vii
誌謝…………………………………………………………………………………ix
表目錄………………………………………………………………………………xii
圖目錄 ……………………………………………………………………………xiii
一、緒論 1
1.冠狀動脈疾病(coronary artery diease) 1
1-1.冠狀動脈疾病的起因 1
1-2.冠狀動脈疾病的診斷 2
1-3.冠狀動脈疾病的治療 2
1-4.何為微型RNA 3
1-5.miRNA的作用機制 3
1-6. miRNA 作為CAD 的生物標記之重要性及優勢 4
1-7. 研究目的 4
二、實驗材料和方法 5
2-1. 實驗材料: 5
2-1-1 病患檢體 5
2-1-2 即時定量聚合酶鍊鎖反應與微型RNA的偵測: 5
2-1-3 萃取RNA所用化學藥劑: 5
2-1-4 數據分析軟體: 6
2-2 實驗方法: 6
2-2-1 實驗步驟: 6
2-2-2 分離血液檢體中的血清 6
2-2-3 微型RNA的萃取 6
2-2-4 微型RNA的RT-qPCR 實驗 7
2-2-5 資料分析 7
2-2-5-1 盒狀圖分析 7
2-2-5-2 接收者操作特征曲線分析 8
2-2-5-3 邏輯式回歸與數據的正規化 8
三、實驗結果 9
3-1.查篩組之微型RNA篩選 9
3-2.訓練組之微型RNA模型的建立 9
3-2-1 訓練組病患背景資料 9
3-2-2 訓練組之微型RNA實驗 9
3-2-3 訓練組之生化指標分析 10
3-2-4 訓練組之多元邏輯回歸分析 11
3-2-5 運用多元邏輯回歸分析建立出的miRNAs及TG組合公式 11
四、結果討論 12
五、參考文獻 14
六、圖 19
七、表
Table 1. Most possible miRNAs which are related to CAD after screening set. 27
Table 2. Distribution of the clinical status of patients in training group. 28
Table 3. Candidate miRNAs profile among training set samples between ACS and non ACS, the ROC analysis of the ratio of miRNA expression. 29
Table 4. The multiple logistic regression of of the ratio of miRNA expressions from training set. 30
八、附錄 31

參考文獻

Ait-Oufella H, Taleb S, Mallat Z, Tedgui A. Recent Advances on the Role of Cytokines in Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 2011;31:969-79
Anand S. A brief primer on microRNAs and their roles in angiogenesis. Vasc Cell 2013;5:2.
Ana Mompeón et al., Disparate miRNA expression in serum and plasma of patients with acute myocardial infarction: a systematic and paired comparative analysis. Scientific Reports volume 10, Article number: 5373 (2020)
Bajan S, Hutvagner G. Regulation of miRNA Processing and miRNA Mediated Gene Repression in Cancer. Microrna. 2014;3(1):10-7.
Boden, WE; Franklin, B; Berra, K; Haskell, WL; Calfas, KJ; Zimmerman,F.H., Wenger,N.K..,(2014). Exercise as a therapeutic intervention in patients with stable ischemic heart disease: an underfilled prescription. The American journal of medicine. October 2014, 127 (10): 905–11.
Bonnefoy,E., Filley,S., Kirkorian,G.,et al. Troponin I, troponin T, or creatine kinase-MB to detect perioperative myocardial damage after coronary artery bypass surgery. Chest 1998;114:482–6.
Cai,X., Hagedorn CH,Cullen,B.R.,(2004). Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA. 2004;10(12):1957–1966.
Camejo G H-CE, Wiklund O, Bondjers G. Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis. Atherosclerosis. 1998; 139(2):205-22.
Cheng C, Wang Q, You W, Chen M, Xia J. MiRNAs as biomarkers of myocardial infarction: a meta-analysis. PLoS One 2014;9:e88566
Croce CM Oncogenes and cancer. N Engl J Med, 2008; 358: 502-511.
D′Alessandra Y, Carena M.C., Spazzafumo L., et al., Diagnostic potential of plasmatic MicroRNA signatures in stable and unstable angina, PLoS One 8 (2013) e80345
Deb,S., Wijeysundera,H.C.,Ko,D.T.,Tsubota,H.;Hill,S.; Fremes,S.E..(2013). Coronary artery bypass graft surgery vs percutaneous interventions in coronary revascularization: a systematic review. JAMA. 20 November 2013, 310 (19): 2086–95.
Fichtlscherer S, De Rosa S, Fox H, et al., Circulating microRNAs in patients with coronary　artery disease. Circ Res . 2010, 107:677-84
Fichtlscherer S, Zeiher AM, Dimmeler S (2011) Circulating microRNAs: biomarkers or mediators of cardiovascular diseases? Arterioscler Thromb Vasc Biol, 2011; 31: 2383–2390.
Filipowicz, W., et. al., Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008;9 :102-14.
Finegold,J.A., Asaria,P.; Francis,D.P., (2012). Mortality from ischaemic heart disease by country, region, and age: Statistics from World Health Organisation and United Nations. International journal of cardiology. 2012-12-04, 168 (2): 934–45.
Garofalo M, Croce CM microRNAs: Master Regulators as Potential Therapeutics in Cancer. Annu Rev Pharmacol Toxicol. 2011;51:25-43. doi: 10.1146
Gidlof O, Smith JG, Miyazu K, Gilje P, Spencer A, Blomquist S, et al. Circulating cardio-enriched microRNAs are associated with long-term prognosis following myocardial infarction. BMC Cardiovasc Disord 2013;13:12
Haver VG, Slart RH, Zeebregts CJ, Peppelenbosch MP, Tio RA Rupture of vulnerable atherosclerotic plaques: microRNAs conducting the orchestra? Trends Cardiovasc Med 2010; 20: 65–71.
Gongol, B., Marin, T., Zhang, J., Wang, S., Sun, W., He, M., . . . Shyy, J. (2019, June 25). Shear stress regulation of miR-93 and miR-484 maturation through nucleolin.
Hoekstra M, Lans C A van der, Halvorsen B, et al., The peripheral blood mononuclear cell microRNA signature of coronary artery disease, Biochem. Biophys. Res. Commun. 394 (2010) 792-797.
Hu R, O′Connell RM MicroRNA control in the development of systemic autoimmunity. Arthritis Res Ther 2013; 15: 202.
Hulsmans M, Sinnaeve P, et al., Decreased miR-181a expression in monocytes of obese patients is associated with the occurrence of metabolic syndrome and coronary artery disease, J. Clin. Endocrinol. Metab. 97 (2012) E1213eE1218
Januzzi,J.L.,Lewandrowski,K., MacGillivray,T.E., et al., (2002). A comparison of cardiac troponin T and creatine kinase-MB for patient after cardiac surgery. J Am Coll Cardiol 2002; 39:1518-23
Wang K, Yuan Y, Cho J-H, McClarty S, Baxter D, Galas DJ (2012) Comparing the MicroRNA Spectrum between Serum and Plasma. PLoS ONE 7(7): e41561.
Kozomara A, Griffiths-Jones S miRBase: integrating microRNA annotation and deep-sequencing data. NAR 2011; 39: D152–D157.
Landskroner-Eiger S, Moneke I, Sessa WC. miRNAs as Modulators of Angiogenesis. Cold Spring Harb Perspect Med 2013;3(2):a006643.
Lee KH, Chen YL, Yeh SD, Hsiao M, Lin JT, et al. MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation. Oncogene 2009; 28: 3360-3370.
Lee,R.C., Feinbaum R.L.,Ambros V.(1993). The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843–854.
Li T, Cao H, Zhuang J, Wan J, et al., Identification of miR-130a, miR-27b and miR-210 as　serum biomarkers for atherosclerosis obliterans. Clin Chim Acta. 2011, 412:66-70.
Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001;104(3):365-72.
Lin PY, Yu SL, Yang PC MicroRNA in lung cancer. Br J Cancer 2010; 103: 1144-1148.
Lin,S.C.,Lu,Y.Y.,Shu,H.C., (2013).Redefinition and classification of myocardial infarction , Journal of Internal Medicine of Taiwan 24(1):1-11
Ling H, Fabbri M, Calin GA MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 2013 12: 847-865.
Lipinski MJ, Baker NC, Escárcega RO, Torguson R, Chen F, Aldous SJ, Christ M, Collinson PO, Goodacre SW, Mair J, Inoue K, Lotze U, Sebbane M, Cristol JP, Freund Y, Chenevier-Gobeaux C, Meune C, Eggers KM, Pracoń R, Schreiber DH, Wu AH, Ordoñez-Llanos J, Jaffe AS, Twerenbold R, Mueller C, Waksman R, Comparison of conventional and high-sensitivity troponin in patients with chest pain: a collaborative meta-analysis, Am Heart J. 2015;169(1):6-16.e6. doi: 10.1016/ j.ahj.2014.10.007. Epub 2014 Oct 22.
Lipinski,M.J., (2015).Comparison of conventional and high-sensitivity troponin in patients with chest pain: a collaborative meta-analysis.Am Heart J. 2015 Jan;169(1):6-16.e6.
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838.
M, Twerenbold R, Reichlin T, Mueller M, Hoeller R, Moehring B, Haaf P, Wildi K, Merk S, Bernhard D, Mueller CZ, Freese M, Freidank H, Campodarve Botet I, Mueller C., Heart-type fatty acid-binding protein in the early diagnosis of acute myocardial infarction Heart. 2013; 99(10):708-14. doi: 10.1136/heartjnl-2012-303325. Epub 2013 Mar 20
Mason DP KR, Hasenstab D, Bowen-Pope DF, Seifert RA, Coats S, Hawkins SM & Clowes AW. Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle cell migration and alters remodeling in the injured rat carotid artery. Circulation research. 1999;85(12):1179-85.
Minami Y, Satoh M, Maesawa C, et al., Effect of atorvastatin on microRNA 221 / 222 expression in endothelial progenitor cells obtained from patients with coronary artery disease. Eur J Clin Invest. 2009, 39:359-67.
Nakamura, K., et. al., Clinical relevance of circulating cell-free microRNAs in ovarian cancer. Mol Cancer, 2016; 15: 48.
Negrini M, Nicoloso MS, Calin GA MicroRNAs and cancer--new paradigms in molecular oncology. Curr Opin Cell Biol 2009; 21: 470-479.
Packard RR LP. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clinical chemistry. 2008;54(1):24-38.
Papageorgiou N., DT, M. Charakida. Prognostic role of miRNAs in coronary artery disease. Curr Top Med Chem. 2013;13:1540-7.
Pasquinelli AE. MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nature Reviews Genetics 2012;13,: 271-82.
Raines EW FN. Thematic review series: The immune system and atherogenesis: Cytokines affecting endothelial and smooth muscle cells in vascular disease Journal of lipid research. 2005; 46(6):1081-92.
Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE, Parathath S, van Gils JM, Rayner AJ, Chang AN, Suarez Y, Fernandez-Hernando C, Fisher EA, Moore KJ. Antagonism of mir-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest. 2011;121:2921–2931.
Reiter M, Twerenbold R, Reichlin T, Mueller M, Hoeller R, Moehring B, Haaf P, Wildi K, Merk S, Bernhard D, Mueller CZ, Freese M, Freidank H, Campodarve Botet I, Mueller C., Heart-type fatty acid-binding protein in the early diagnosis of acute myocardial infarction Heart. 2013 May;99(10):708-14. doi: 10.1136/heartjnl-2012-303325. Epub 2013 Mar 20
Small EM, Olson EN Pervasive roles of microRNAs in cardiovascular biology. Nature 2011; 469: 336–342
Thibault Dufourd et al. Plasma or serum? A qualitative study on rodents and humans using high-throughput microRNA sequencing for circulating biomarkers. Biology Methods and Protocols, 2019, 1–10
Wahid,F., Shehzad,A., Khan,T., Kim,Y.Y.,(2010). MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta. 2010;1803:1231–1243.

指導教授

馬念涵(Nian-Han Ma)

審核日期

2020-8-19

推文